From: Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones
A. mAbs used | Target on Env | |||||
---|---|---|---|---|---|---|
4E10 | MPER* | |||||
2F5 | MPER* | |||||
2G12 | V3 glycans†| |||||
b12 | CD4bs†| |||||
PG9 | V1/V2 loop†| |||||
PG16 | V1/V2 loop†| |||||
B. env strains used for Pseudovirus | Clade | Subject identifier | Accession Number | Gender | Mode of Transmission | Fiebig Stage b |
SF162 | B | N.A. | EU123924 | Male | N/A | VI |
AC10.0.29 | B | AC10.0 | AY835446 | Male | MSMa | III |
REJO4541.67 | B | REJO4541 | AY835449 | Male | HSX | II |
RHPA4259.7 | B | RHPA4256 | AY835447 | Female | HSX | ≤ V |
THRO4156.18 | B | THRO4156 | AY835448 | Male | MSM | II |
C. IMC of T/F strains | Â | Â | Â | Â | Â | Â |
CH040.c | B | 700010040 | JN944939 | Male | MSM | T/F IMCc |
CH058.c | B | 700010058 | JN944940 | Male | MSM | T/F IMCc |
CH077.t | B | 700010077 | JN944941 | Male | MSM | T/F IMCc |
REJO.c | B | REJO4541 | JN944943 | Male | HSX | T/F IMCc |
RHPA.c | B | RHPA4256 | JN944944 | Female | HSX | T/F IMCc |
THRO.c | B | THRO4156 | JN944947 | Male | MSM | T/F IMCc |